124 related articles for article (PubMed ID: 33547722)
1. 'Case of the Month' from the National Cancer Institute, Bethesda, MD, USA: investigating genetic aberrations in a patient with high-risk prostate cancer.
O'Connor LP; Lebastchi AH; Fasaye GA; Dikoglu E; Daneshvar MA; Ahdoot M; Merino MJ; Pinto PA
BJU Int; 2021 Feb; 127(2):171-174. PubMed ID: 33547722
[No Abstract] [Full Text] [Related]
2. The role of magnetic resonance image guided prostate biopsy in stratifying men for risk of extracapsular extension at radical prostatectomy. Raskolnikov D, George AK, Rais-Bahrami S, Turkbey B, Siddiqui MM, Shakir NA, Okoro C, Rothwax JT, Walton-Diaz A, Sankineni S, Su D, Stamatakis L, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Center for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, Maryland; e-mail: pintop@mail.nih.gov.J Urol. 2015 Jul;194(1):105-11. [Epub 2015 Jan 23]. doi: 10.1016/j.juro.2015.01.072.
Scott E
Urol Oncol; 2017 Mar; 35(3):121. PubMed ID: 28159491
[TBL] [Abstract][Full Text] [Related]
3. How I Do It: Genetic counseling and genetic testing for inherited prostate cancer.
Giri VN; Gross L; Gomella LG; Hyatt C
Can J Urol; 2016 Apr; 23(2):8247-53. PubMed ID: 27085833
[TBL] [Abstract][Full Text] [Related]
4. A cross-section of UK prostate cancer diagnostics during the coronavirus disease 2019 (COVID-19) era - a shifting paradigm?
Stroman L; Cathcart P; Lamb A; Challacombe B; Popert R
BJU Int; 2021 Jan; 127(1):30-34. PubMed ID: 32981180
[No Abstract] [Full Text] [Related]
5. Practice guidelines for prostate cancer.
Ahlering T; Parker R; Kumar S; Taylor C; Gilden R; Figlin RA
Cancer J Sci Am; 1996; 2(3A Suppl):S77-86. PubMed ID: 9166527
[No Abstract] [Full Text] [Related]
6. National Cancer Institute Prostate Cancer Genetics Workshop.
Catalona WJ; Bailey-Wilson JE; Camp NJ; Chanock SJ; Cooney KA; Easton DF; Eeles RA; FitzGerald LM; Freedman ML; Gudmundsson J; Kittles RA; Margulies EH; McGuire BB; Ostrander EA; Rebbeck TR; Stanford JL; Thibodeau SN; Witte JS; Isaacs WB
Cancer Res; 2011 May; 71(10):3442-6. PubMed ID: 21558387
[TBL] [Abstract][Full Text] [Related]
7. Hereditary prostate cancer.
Bratt O
BJU Int; 2000 Mar; 85(5):588-98. PubMed ID: 10735934
[No Abstract] [Full Text] [Related]
8. [Prostate cancer, generalized screening soon?].
Girault V
Presse Med; 2002 Aug; 31(26):1205. PubMed ID: 12212509
[No Abstract] [Full Text] [Related]
9. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
Carroll PH; Mohler JL
J Natl Compr Canc Netw; 2018 May; 16(5S):620-623. PubMed ID: 29784740
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects.
Rodgers L; Peer CJ; Figg WD
Cancer Biol Ther; 2017 Jul; 18(7):470-472. PubMed ID: 28475407
[TBL] [Abstract][Full Text] [Related]
11. Special report: recent developments in prostate cancer genetics and genetic testing.
Technol Eval Cent Assess Program Exec Summ; 2009 Jan; 23(7):1-3. PubMed ID: 19297804
[No Abstract] [Full Text] [Related]
12. [What about the contribution of genetics in prostate cancer screening?].
Nau JY
Rev Med Suisse; 2014 Jul; 10(437):1474-5. PubMed ID: 25141570
[No Abstract] [Full Text] [Related]
13. The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer.
Eisenberg ML; Cowan JE; Davies BJ; Carroll PR; Shinohara K
Urol Oncol; 2011; 29(2):171-6. PubMed ID: 19362864
[TBL] [Abstract][Full Text] [Related]
14. Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6.
Bar-Shira A; Matarasso N; Rosner S; Bercovich D; Matzkin H; Orr-Urtreger A
Prostate; 2006 Jul; 66(10):1052-60. PubMed ID: 16598737
[TBL] [Abstract][Full Text] [Related]
15. HPC2 variants and screen-detected prostate cancer.
Vesprini D; Nam RK; Trachtenberg J; Jewett MA; Tavtigian SV; Emami M; Ho M; Toi A; Narod SA
Am J Hum Genet; 2001 Apr; 68(4):912-7. PubMed ID: 11254449
[TBL] [Abstract][Full Text] [Related]
16. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives.
Valeri A; Cormier L; Moineau MP; Cancel-Tassin G; Azzouzi R; Doucet L; Baschet F; Cussenot I; L'Her J; Berthon P; Mangin P; Cussenot O; Morin JF; Fournier G
J Urol; 2002 Aug; 168(2):483-7. PubMed ID: 12131293
[TBL] [Abstract][Full Text] [Related]
17. [Characterisation of families with hereditary prostate cancer in the Netherlands].
Meulenbeld HJ; Verhage BA; Kil PJ; Kiemeney LA; Vasen HF
Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1938-42. PubMed ID: 12404910
[TBL] [Abstract][Full Text] [Related]
18. Life insurance and genetic testing for prostate cancer: what advice for patients?
Meyer JP; Westera J
ANZ J Surg; 2012 Apr; 82(4):194-6. PubMed ID: 22510170
[No Abstract] [Full Text] [Related]
19. A review of targeted screening for prostate cancer: introducing the IMPACT study.
Mitra AV; Bancroft EK; Eeles RA;
BJU Int; 2007 Jun; 99(6):1350-5. PubMed ID: 17419707
[No Abstract] [Full Text] [Related]
20. Five genetic variants associated with prostate cancer.
Vickers A; Lilja H; Scardino P
N Engl J Med; 2008 Jun; 358(25):2740; author reply 2741. PubMed ID: 18572449
[No Abstract] [Full Text] [Related]
[Next] [New Search]
